CSO – Barcelona (Hybrid): Lead Discovery to Early Clinical, Equity

S3 Science Recruitment; Madrid; Híbrido; EUR 125.000 - 150.000; Jornada completa

Descripción de la vacante

A leading biotech recruitment firm is seeking a Chief Scientific Officer (CSO) for a dynamic company in Barcelona. This pivotal role involves shaping the scientific strategy and leading R&D efforts. Candidates need a PhD or MD/PhD and proven leadership experience in biotech or pharma. The position offers competitive executive compensation plus equity participation and is based in one of Europe's leading life science hubs. It’s an opportunity to significantly influence a high-potential biotech during a critical growth stage.

Servicios

Significant ownership and influence at executive leadership level

Opportunity for meaningful equity participation

Exceptional quality of life in Barcelona

Formación

• Proven leadership experience at executive or senior R&D leadership level within biotech or pharma.
• Strong track record of advancing programmes from discovery through IND-enabling / early clinical stages.
• Demonstrated ability to operate in fast-paced, capital-efficient environments.

Responsabilidades

• Set and own the scientific vision and R&D strategy, aligned with corporate and investor objectives.
• Lead discovery, preclinical, and translational activities, ensuring scientific excellence and disciplined execution.
• Act as the scientific authority internally and externally.

Conocimientos

Leadership

Strategic Thinking

Communication

Decision Making

Educación

PhD or MD / PhD in a relevant scientific discipline

Descripción del empleo

A leading biotech recruitment firm is seeking a Chief Scientific Officer (CSO) for a dynamic company in Barcelona. This pivotal role involves shaping the scientific strategy and leading R&D efforts. Candidates need a PhD or MD/PhD and proven leadership experience in biotech or pharma. The position offers competitive executive compensation plus equity participation and is based in one of Europe's leading life science hubs. It’s an opportunity to significantly influence a high-potential biotech during a critical growth stage.